- Truist Securities downgraded ALNY to Hold from Buy.
- Alnylam Pharmaceuticals downgraded to Hold from Buy by Truist Securities.
Truist Securities cut its rating on Alnylam Pharmaceuticals to Hold from Buy. The downgrade was reported Monday. No price target or reasoning was disclosed.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.